Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752558 | 1.00 | CYP2C9 (0.43) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL9185404 | 0.81 | CYP2C9 (0.59) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL27987895 | 0.80 | ALOX5 (0.51) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL8576653 | 0.80 | ALOX5 (0.51) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL5270052 | 0.78 | TSHR (0.46) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL6752302 | 0.78 | MAOA (0.44) | HPGDLMNAGAAALDH1A1 | |
| SCHEMBL27725216 | 0.77 | CYP2C9 (0.47) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL29628554 | 0.77 | MMP2 (0.46) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL6752303 | 0.76 | CYP2C9 (0.43) | CYP2C9CYP2C19HPGDHTTALOX5 | |
| SCHEMBL10748377 | 0.76 | SSTR4 (0.41) | CYP2C9CYP2C19HPGDHTTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211508-B2 | radiation curing ink cures with high sensitivity to form a high quality, durable image resistant to cracking, peeling and has excellent impact resistance, flexibility, and adhesion; cyclic monofunctional acrylic or N-vinyl monomers | FUJIFILM CORPORATION (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8183415-B2 | Methods of synthesizing cinacalcet and salts thereof | AMGEN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2011-11-17 | — | — | US | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | CYP2C9 350/4885CYP2C19 548/4885HPGD 2835/4885 |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | CYP2C9 350/4885CYP2C19 548/4885HPGD 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.